Biopharmaceutical Company MediciNova has announced additional positive clinical data from its SPRINT-MS phase IIB trial of MN-166 (ibudilast) in progressive multiple sclerosis (PMS)...Read more - http://www.ms-uk.org/ms-drug-ibudilast- ... e-ms-trial
